

2. (Amended One Time) The angiogenesis-inhibitory tripeptide of Claim 1, wherein:

- (a) said first amino acid is selected from the group consisting of Ser, Thr, Cys, and diaminopropionic acid;
- (b) said second amino acid is selected from the group consisting of Asn and Gln; and
- (c) said third amino acid is selected from the group consisting of Ser, Thr, Cys, and diaminopropionic acid.

3. (Amended One Time) The angiogenesis-inhibitory tripeptide of Claim 1, wherein:

- (a) said first amino acid is Ser;
- (b) said second amino acid is Asn or Gln; and
- (c) said third amino acid is Ser.

5. (Amended One Time) The angiogenesis-inhibitory tripeptide of Claim 1, wherein the first amino acid is an amino-terminal and the third amino acid is a carboxy-terminal, wherein:

- (a) the amino-terminal is capped with a compound selected from the group consisting of acetyl, benzoyl, alkylsulfonyl, arylsulfonyl, alkylaminoacyl, arylaminoacyl, and formyl; and
- (b) the carboxy-terminal is capped with a compound selected from the group consisting of  $\text{NH}_2$ , OH, and  $\text{NHR}$ , wherein R is selected from the group consisting of alkyl and aryl.

6. (Amended One Time) The angiogenesis-inhibitory tripeptide of Claim 5, wherein the amino-terminal is capped with an acetyl group and the carboxy-terminal is capped with an amide group.

14. (Amended One Time) The method of Claim 9, wherein the angiogenesis is associated with a condition selected from the group consisting of ocular neovascular diseases, choroidal neovascular diseases, retina neovascular diseases, neovascularization of the angle, Bartonellosis, chronic inflammation, osteoarthritis, rheumatoid arthritis, atherosclerosis phemphigoid, trachoma, and Osler-Webber-Rendu disease.

21. (Amended One Time) The method of Claim 11, wherein said tripeptide is administered in conjunction with a therapeutic compound, the therapeutic compound being selected from the group consisting of chemotherapeutics, antibiotics, antivirals, anti-inflammatories, targeting compounds, cytokines, immunotoxins, anti-tumor antibodies, angiogenic inhibitors, anti-edema agents, and radiosensitizers.

23. (New Claim) An angiogenesis-inhibitory compound, comprising a capped tripeptide of formula aa1-aa2-aa3, having a first amino acid (aa1), a second amino acid (aa2) and a third amino acid (aa3), wherein:

- (a) said first amino acid is selected from the group consisting of Ser, Thr, Ala, Phe, Tyr, Cys, Gly, Leu, Lys, Pro, Arg, Gln, Glu, Asp, Asn, His, Met, Ile, Trp, Val, diaminopropionic acid and *trans*-4-hydroxy-proline and wherein said first amino acid is capped with a compound selected from the group consisting of peptide and polymer;
- (b) said second amino acid is selected from the group consisting of Asn, Ala, Gly, Asp, Glu, Gln diaminopropionic acid and *trans*-4-hydroxy-proline; and
- (c) said third amino acid is selected from the group consisting of Ser, Thr, Ala, Phe, Tyr, Cys, Gly, Leu, Lys, Pro, Arg, Gln, Glu, Asp, Asn, His, Met, Ile, Trp, Val, diaminopropionic acid and *trans*-4-hydroxy-proline and wherein said third amino acid is capped with a compound selected from the group consisting of NH<sub>2</sub>, OH, and NHR, wherein R is selected from the group consisting of alkyl and aryl;

and wherein the tripeptide is not Arg-Gly-Asp.

#### REMARKS

Claims 1-22 are pending in the application. Claims 4-6 are objected to. Claims 1, 2, 3, 5, 6, 14 and 21 have been amended to more clearly define Applicants' invention. A marked-up version of the amendments to the claims is found on a separate sheet attached to this amendment titled "Version with Markings to Show Changes Made". New Claim 23 has been added. No new matter has been added to the application.